Phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors for the treatment of inflammation and autoimmune disease

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 4, Issue 1, 2010, Pages 1-15

  Venable, Jennifer D ^a   Ameriks, Michael K ^a   Blevitt, Jonathan M ^a   Thurmond, Robin L ^a   Fung Leung, Wai Ping ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

2 aminoheterocycles; Arthritis; Autoimmune disease; Chemotaxis; Inflammation; Knockout mice; Macrophages; Mast cells; Neutrophils; Oxidative burst; Phosphoinositide 3 kinase gamma; Pi3k inhibitors; Signaling; T cells; Thiazolidinones

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; BENZOFURAN DERIVATIVE; G PROTEIN COUPLED RECEPTOR; HETEROCYCLIC COMPOUND; PF 376304; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHOINOSITIDE 3 KINASE GAMMA INHIBITOR; PIK 124; TG100 115; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ENZYME INHIBITOR; ISOENZYME; PHOSPHATIDYLINOSITOL 3-KINASE GAMMA;

ACUTE HEART INFARCTION; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CELL MIGRATION; CRYSTAL STRUCTURE; DRUG SELECTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; INFLAMMATORY DISEASE; LEUKOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MAST CELL DEGRANULATION; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; ENZYME SPECIFICITY; INFLAMMATION; PATENT; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; AUTOIMMUNE DISEASES; ENZYME INHIBITORS; HUMANS; INFLAMMATION; ISOENZYMES; PATENTS AS TOPIC; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THIAZOLIDINEDIONES;

EID: 77953116018     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221310789895603     Document Type: Article

References (100)

1. Marone R, Cmiljanovic V, Giese B, et al. Targeting phosphoinositide 3-kinase: Moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-185.
2. Backer JM. Substrate specificity: PI(3)Kgamma has it both ways. Nat Cell Biol 2005; 7: 773-774.
3. Thomas M, Owen C. Inhibition of PI-3 kinase for treating respiratory disease: Good idea or bad idea? Curr Opin Pharmacol 2008; 8: 267-274.
4. Ghigo A, Hirsch E. Isoform selective phosphoinositide 3-kinase and inhibitors and their therapeutic potential. Recent Pat Inflamm Allergy Drug Discov 2008; 2: 1-10.
5. Bernstein HG, Keilhoff G, Reiser M, et al. Tissue distribution and subcellular localization of a G-protein activated phosphoinositide 3-kinase: An immunohistochemical study. Cell Mol Biol (Noisy-legrand) 1998; 44: 973-983.
6. Vecchione C, Patrucco E, Marino G, et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J Exp Med 2005; 201: 1217-1228.
7. Patrucco E, Notte A, Barberis L, et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinasedependent and -independent effects. Cell 2004; 118: 375-387.
8. Stephens LR, Eguinoa A, Erdjument-Bromage H, et al. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 1997; 89: 105-114.
9. Maier U, Babich A, Nurnberg B. Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. J Biol Chem 1999; 274: 29311-29317.
10. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
11. Hannigan M, Zhan L, Li Z, et al. Neutrophils lacking phosphoinositide 3-kinase gamma show loss of directionality during N-formyl-Met-Leu-Phe-induced chemotaxis. Proc Natl Acad Sci USA 2002; 99: 3603-3608.
12. Cote JF, Motoyama AB, Bush JA, et al. A novel and evolutionarily conserved PtdIns(3, 4, 5)P3-binding domain is necessary for DOCK180 signalling. Nat Cell Biol 2005; 7: 797-807.
13. Ridley AJ, Paterson HF, Johnston CL, et al. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992; 70: 401-410.
14. Wennerberg K, Der CJ. Rho-family GTPases: It's not only Rac and Rho (and I like it). J Cell Sci 2004; 117: 1301-1312.
15. Dormann D, Weijer CJ. Imaging of cell migration. EMBO J 2006; 25: 3480-3493.
16. Wong K, Pertz O, Hahn K, et al. Neutrophil polarization: Spatiotemporal dynamics of RhoA activity support a selforganizing mechanism. Proc Natl Acad Sci USA 2006; 103: 3639-3644.
17. Condliffe AM, Davidson K, Anderson KE, et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 2005; 106: 1432-1440.
18. Baumer AT, Ten Freyhaus H, Sauer H, et al. Phosphatidylinositol 3-kinase-dependent membrane recruitment of Rac-1 and p47phox is critical for alpha-platelet-derived growth factor receptor-induced production of reactive oxygen species. J Biol Chem 2008; 283: 7864-7876.
19. Laffargue M, Calvez R, Finan P, et al. Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 2002; 16: 441-451.
20. Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000; 287: 1040-1046.
21. Alcazar I, Marques M, Kumar A, et al. Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation. J Exp Med 2007; 204: 2977-2987.
22. Li Z, Jiang H, Xie W, et al. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 2000; 287: 1046-1049.
23. Ferguson GJ, Milne L, Kulkarni S, et al. PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol 2007; 9: 86-91.
24. Hirsch E, Katanaev VL, Garlanda C, et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000; 287: 1049-1053.
25. Pinho V, de Castro RR, Amaral FA, et al. Tissue-and stimulusdependent role of phosphatidylinositol 3-kinase isoforms for neutrophil recruitment induced by chemoattractants in vivo. J Immunol 2007; 179: 7891-7898.
26. Randis TM, Puri KD, Zhou H, et al. Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur J Immunol 2008; 38: 1215-1224.
27. Suire S, Condliffe AM, Ferguson GJ, et al. Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat Cell Biol 2006; 8: 1303-1309.
28. Thomas MJ, Smith A, Head DH, et al. Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur J Immunol 2005; 35: 1283-1291.
29. Jones GE, Prigmore E, Calvez R, et al. Requirement for PI 3-kinase gamma in macrophage migration to MCP-1 and CSF-1. Exp Cell Res 2003; 290: 120-131.
30. Maus UA, Backi M, Winter C, et al. Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. Am J Respir Crit Care Med 2007; 175: 958-966.
31. Pomel V, Klicic J, Covini D, et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem 2006; 49: 3857-3871.
32. Liu L, Puri KD, Penninger JM, et al. Leukocyte PI3Kgamma and PI3Kdelta have temporally distinct roles for leukocyte recruitment in vivo. Blood 2007; 110: 1191-1198.
33. Smith DF, Deem TL, Bruce AC, et al. Leukocyte phosphoinositide-3 kinase {gamma} is required for chemokine-induced, sustained adhesion under flow in vivo. J Leukoc Biol 2006; 80: 1491-1499.
34. Ferrandi C, Ardissone V, Ferro P, et al. Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment. J Pharmacol Exp Ther 2007; 322: 923-930.
35. Lanni TB Jr, Greene KL, Kolz CN, et al. Design and synthesis of phenethyl benzo[1, 4]oxazine-3-ones as potent inhibitors of PI3Kinasegamma. Bioorg Med Chem Lett 2007; 17: 756-760.
36. Puri KD, Doggett TA, Huang CY, et al. The role of endothelial PI3Kgamma activity in neutrophil trafficking. Blood 2005; 106: 150-157.
37. Yum HK, Arcaroli J, Kupfner J, et al. Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury. J Immunol 2001; 167: 6601-6608.
38. Camps M, Ruckle T, Ji H, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11: 936-943.
39. Barber DF, Bartolome A, Hernandez C, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11: 933-935.
40. Gatson NN, Ji H, Gienapp IE, et al. A distinct role for PI3Kgamma in suppressing the development and progression of Experimental autoimmune encephalomyelitis (EAE). J Immunol 2007; 178: 129-130.
41. Rodrigues DH, Vilela M, Sachs D, et al. Investigation of nociception and leukocyte recruitment in an experimental model of multiple sclerosis in a PI3 kinase-deficient mice. XXXI Meeting of Brazilian Society for Immunology 2006;36-36.
42. Chang JD, Sukhova GK, Libby P, et al. Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proc Natl Acad Sci USA 2007; 104: 8077-8082.
43. Fougerat A, Gayral S, Gourdy P, et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 2008; 117: 1310-1317.
44. Lupia E, Goffi A, De Giuli P, et al. Ablation of phosphoinositide 3-kinase-gamma reduces the severity of acute pancreatitis. Am J Pathol 2004; 165: 2003-2011.
45. Lezama-Davila CM, Isaac-Marquez AP, Barbi J, et al. Role of phosphatidylinositol-3-kinase-gamma (PI3Kgamma)-mediated pathway in 17beta-estradiol-induced killing of L. mexicana in macrophages from C57BL/6 mice. Immunol Cell Biol 2008; 86: 539-543.
46. Patrucco E, Notte A, Barberis L, et al. PI3Kg modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004; 118: 375-387.
47. Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase g/d inhibition limits infarct size after myocardial ischemia/ reperfusion injury. Proc Natl Acad Sci USA 2006; 103: 19866-19871.
48. Zhang X, Crespo A, Fernandez A. Turning promiscuous kinase inhibitors into safer drugs. Trends Biotechnol 2008; 26: 295-301.
49. Walker EH, Pacold ME, Perisic O, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000; 6: 909-919.
50. Walker EH, Perisic O, Ried C, et al. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999; 402: 313-320.
51. Zvelebil MJ, Waterfield MD, Shuttleworth SJ. Structural analysis of PI3-kinase isoforms: Identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. Arch Biochem Biophys 2008; 477: 404-410.
52. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006; 125: 733-747.
53. Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
54. Fuchikami K, Togame H, Sagara A, et al. A versatile highthroughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase gamma. J Biomol Screen 2002; 7: 441-450.
55. Tang X, Downes CP. Purification and characterization of Gbetagamma-responsive phosphoinositide 3-kinases from pig platelet cytosol. J Biol Chem 1997; 272: 14193-14199.
56. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996; 16: 1722-1733.
57. Wymann MP, Zvelebil M, Laffargue M. Phosphoinositide 3-kinase signalling-which way to target? Trends Pharmacol Sci 2003; 24: 366-376.
58. Vlahos CJ, Matter WF, Hui KY, et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-5248.
59. Knight ZA, Shokat KM. Chemically targeting the PI3K family. Biochem Soc Trans 2007; 35: 245-249.
60. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
61. Rueckle, T., Jiang, X., Gaillard, P., Church, D., Vallotton, T.: WO2004007491 (2004).
62. Rueckle, T., Shaw, J., Church, D., Covini, D.: WO2005011686 (2005).
63. Rueckle, T., Quattropani, A., Pomel, V., Dorbais, J., Covini, D., Bischoff, A.: WO2006024666 (2006).
64. Barvian, N. C., Kolz, C. N., Para, K.S., Patt, W. C., Visnick, M.: WO2004052373 (2004).
65. Gogliotti, R. D., Muccioli, K. L., Para, K.S., Visnick, M.: WO2004056820 (2004).
66. Ghose AK, Herbertz T, Pippin DA, et al. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J Med Chem 2008; 51: 5149-5171.
67. Bruce, I., Finan, P., Leblanc, C., McCarthy, C., Whitehead, L., Blair, N. E., Bloomfield, G. C., Hayler, J., Kirman, L., Oza, M. S., Shukla, L.: WO03072557(2003).
68. Bloomfield, G. C., Bruce, I., Hayler, J. F., Leblanc, C., Le Grand, D. M., McCarthy, C.: WO2005021519 (2005).
69. Budd, E., Fox, H.J., Ian B., Legrand, D. M. N. H., Cox, B., Budd, E., Fox, H. J., Ian, B., Legrand, D.M.N. H., Cox, B.: WO2007134827(2007).
70. Bloomfield, G. C., Bruce, I., Leblanc, C., Oza, M.S., Whithead, L., Cuenoud, B., Keller, T., H., Kirman, L., McCarthy, C., Woodward, G.E.: WO20060148822 (2006).
71. Bruce, I., Cuenoud, B., Keller, T.H., Pilgrim, G. E., Press, N., Le Grand, D. M., Ritchie, C., Valade, B., Hayler, J., Budd, E., WO20070032487 (2007).
72. Budd, E., Hatto, J. D.I., Hayler, J. F., Legrand, D. M., Valade, B.: WO2007068473 (2007).
73. Bruce, I., Weitz, S.G.: WO2008000421 (2008).
74. Steffen, B.: WO20060106013 (2006).
75. Brandl, T., Maier U., Hoffmann, M., Scheuerer, S., Joergensen, A.T., Pautsch, A., Breitfelder, S., Grauert, M., Hoenke, C., Erb, K., Pieper, M., Pragst I.: WO2007115929 (2007).
76. Maier, U., Grauert, M., Hoffmann, M., Hoenke, C., Joergensen, A. T., Pautsch, A., Brandl, T., Breitfelder, S., Scheuerer, S., Erb, K., Pieper, M., Pragst, I.: WO2007115930 (2007).
77. Breitfelder, S., Maier, U., Hoenke, C., Joergensen, A.T., Pautsch, A., Brandl, T., Grauert, M., Hoffmann, M., Scheuerer, S., Erb, K., Pieper, M., Pragst I.: WO2007115931 (2007).
78. Wang, T., Green, J., Cornebise, M., Ledford, B., Parsons, J., Tanner, A., Westcott, J.: WO2008027584 (2008).
79. Moffat, D. C. F., Davies, S., Alesso, S. M., Launay, D. F. M.: WO2007129048 (2007).
80. Quattropani, A., Rueckle, T., Schwarz, M., Dorbais, J., Sauer, W., Cleva, C., Desforges, G.: WO2005068444 (2005).
81. Quattropani, A., Pomel, V., Rueckle, T., Grippi-Vallotton, T.: WO2007082956 (2007).
82. Alexander, R. P., Aujla, P., Batchelor, M. J., Brookings, D.C., Buckley, G.M., Crepy, K. V. L., Kulisa, C.L., Turner, J.P.: WO2006114606 (2006).
83. Alexander, R.P., Bailey, S., Brand, S., Brookings, D. C., Brown, J.A., Haughan, A.F., Kinsella, N., Lowe, C., Mack, S. R., Pitt, W.R., Richard, M. D., Sharpe, A., Tait, L.J.: WO2007141504 (2007).
84. Alexander, R.P., Aujla, P. S., Crepy, K.V. L., Foley, A.M., Franklin, R.J., Haughan, A. F., Horsley, H. T., Jones, W.M., Lallemand, B. I. L., Mack, S.R., Morgan, T., Pasau, P. M. G., Phillips, D.J., Sabin, V. M., Buckley, G. M., Jenkins, K., Perry, B. G.: WO2008001076 (2008).
85. Buckley, G.M., Morgan, T., Sabin, V.M.: WO2008044022 (2008).
86. Alexander, R.P., Brown, J. A., Crepy, K.V. L., Mack, S.R.: WO2008047109 (2008).
87. Alexander R, Balasundaram A, Batchelor M, et al. 4-(1, 3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase. Bioorg Med Chem Lett 2008; 18: 4316-4320.
88. Perry B, Alexander R, Bennett G, et al. Achieving multi-isoform PI3K inhibition in a series of substituted 3, 4-dihydro-2H-benzo[1, 4]oxazines. Bioorg Med Chem Lett 2008; 18: 4700-4704.
89. Perry B, Beevers R, Bennett G, et al. Optimization of a series of multi-isoform PI3 kinase inhibitors. Bioorg Med Chem Lett 2008; 18: 5299-5302.
90. Gaillard, P., Quattropani A., Pomel, V., Rueckle, T., Klicic, J., Church, D.: WO2007023186 (2007).
91. Wilson, F., Ramsden, N., Bell, K., Cansfield, A., Burckhardt, S., Taylor, J., Sunose, M., Middlemiss, D.: WO2008025821 (2008).
92. Giovannini, R., Frattini, S., Brandl, T., Breitfelder, S., Cereda, E., Grauer, M., Hoffmann, M., Joergensen, A. T., Maier U., Pautsch A., Quai M., Scheuerer S.: WO2008092831 (2008).
93. Bruce I., Hayler, J. F., Bloomfield, G. C., Edwards, L., Cox, B., Howsham, C.: WO2007134828 (2007).
94. Bruendl, M. M., Gogliotti, R. D., Goodman, A. P., Reichard, G. A.: US20080255162 (2008).
95. Shimada, M., Murata, T., Fuchikami, K., Tsujishita, H., Omori, N., Kato, I., Miura, M., Urbahns, K., Gantner, F., Bacon, K.: WO2004029055 (2004).
96. Gogliotti, R. D., Lee, H. T., Sexton, K. E., Visnick, M.: WO2004108709 (2004).
97. Bruendl, M. M., Connolly, M. K., Goodman, A. P., Gogliotti, R. D., Lee, H.T., Plummer, M. S., Sexton, K.E., Reichard, G. A., Visnick, M., Wilson, M. W., Shahripour, A.B.: WO2004108715 (2004).
98. Connolly, M.K., Cogliotti, R. D., Hurt, C. R., Reichard, G. A., Visnick, M.: WO2005023800 (2005).
99. Connolly, M. K., Gogliotti, R.D., Plummer, M. S., Visnick, M.: WO2005042519 (2005).
100. Robertson DG, Datta K, Wells D, et al. Metabonomic evaluation of metabolic dysregulation in rats induced by PF 376304, a novel inhibitor of phosphoinositide 3-kinase. Chem Res Toxicol 2007; 20: 1871-1877.